Form 4: Elanco Director Receives Annual Equity Award

Elanco Animal Health Inc. director Deborah Turner Kochevar was granted 10,314 deferred stock units as an annual equity award.

Summary

• Deborah Turner Kochevar, a Director of Elanco Animal Health Inc., received an annual equity award.
• The award consists of 10,314 deferred stock units of common stock.
• The transaction date for this grant is November 28, 2025, with a price of $0 per unit.
• Following this transaction, Kochevar beneficially owns 89,714 shares of common stock.
• This grant is part of the annual equity awards for non-employee members of the Issuer's Board of Directors.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation event, indicating stable corporate governance practices and aligning director interests with shareholders. It does not present significant positive or negative financial implications for the company's operational performance.

Positives

• The grant of equity to a director aligns director incentives with shareholder interests.
• The award is part of a standard annual equity compensation for non-employee directors, indicating stable corporate governance practices.

Future Outlook

This filing primarily reports a scheduled insider transaction and does not contain forward-looking statements regarding the company's financial performance or strategic outlook. It only indicates a future transaction date for the grant.

Industry Context

This is a routine insider transaction, specifically an equity grant to a non-employee director, which is a common practice across publicly traded companies as part of their standard compensation structure for board members. It does not provide specific insights into broader industry trends within the animal health sector.

Comparison to Industry Standards

• Granting equity to non-employee directors is a standard practice in corporate governance across various industries, including animal health, to align their interests with long-term shareholder value.
• The specific amount of 10,314 deferred stock units would typically be evaluated against peer companies' director compensation packages to assess if it falls within industry norms, but this filing alone does not provide the necessary comparative data for such an assessment.

Corporate Governance

Related Party Transactions

• Grant of 10,314 deferred stock units to Deborah Turner Kochevar, a non-employee director, as part of her annual equity compensation. This is a standard related party transaction for director remuneration.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests more closely with those of the shareholders through increased equity ownership.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports a routine annual equity grant to a non-employee director, which is a standard corporate governance practice. It does not contain information that would fundamentally alter the investment thesis for Elanco Animal Health Inc., thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Elanco Animal Health, ELAN, Form 4, Insider Trading, Equity Award, Deferred Stock Units, Director Compensation, Stock Grant, Corporate Governance